Stock Research for ZIOP

ZIOP

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

ZIOP Stock Chart & Research Data

The ZIOP chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ZIOP chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


ZIOP Due diligence Resources & Stock Charts

The ZIOP stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View ZIOP Detailed Price Forecast - CNN Money CNN View ZIOP Detailed Summary - Google Finance
Yahoo View ZIOP Detailed Summary - Yahoo! Finance Zacks View ZIOP Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View ZIOP Trends & Analysis - Trade-Ideas Barrons View ZIOP Major Holders - Barrons
NASDAQ View ZIOP Call Transcripts - NASDAQ Seeking View ZIOP Breaking News & Analysis - Seeking Alpha
Spotlight View ZIOP Annual Report - CompanySpotlight.com OTC Report View ZIOP OTC Short Report - OTCShortReport.com
TradeKing View ZIOP Fundamentals - TradeKing Charts View ZIOP SEC Filings - Bar Chart
WSJ View Historical Prices for ZIOP - The WSJ Morningstar View Performance/Total Return for ZIOP - Morningstar
MarketWatch View the Analyst Estimates for ZIOP - MarketWatch CNBC View the Earnings History for ZIOP - CNBC
StockMarketWatch View the ZIOP Earnings - StockMarketWatch MacroAxis View ZIOP Buy or Sell Recommendations - MacroAxis
Bullish View the ZIOP Bullish Patterns - American Bulls Short Pains View ZIOP Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View ZIOP Stock Mentions - StockTwits PennyStocks View ZIOP Stock Mentions - PennyStockTweets
Twitter View ZIOP Stock Mentions - Twitter Invest Hub View ZIOP Investment Forum News - Investor Hub
Yahoo View ZIOP Stock Mentions - Yahoo! Message Board Seeking Alpha View ZIOP Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for ZIOP - SECform4.com Insider Cow View Insider Transactions for ZIOP - Insider Cow
CNBC View ZIOP Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for ZIOP - OTC Markets
Yahoo View Insider Transactions for ZIOP - Yahoo! Finance NASDAQ View Institutional Holdings for ZIOP - NASDAQ


Stock Charts

FinViz View ZIOP Stock Insight & Charts - FinViz.com StockCharts View ZIOP Investment Charts - StockCharts.com
BarChart View ZIOP Stock Overview & Charts - BarChart Trading View View ZIOP User Generated Charts - Trading View




Latest Financial News for ZIOP


Ziopharm Oncology Announces Changes to Board of Directors and Management Team
Posted on Tuesday October 16, 2018

BOSTON, Oct. 16, 2018 (GLOBE NEWSWIRE) --  Ziopharm Oncology, Inc. (ZIOP), a biotechnology company focused on development of next generation immunotherapies utilizing gene- and cell-based therapies to treat patients with cancer, today announced changes to its Board of Directors and management team. Ziopharm’s Chief Executive Officer Laurence Cooper, M.D., Ph.D, is appointed to the Board of Directors effective immediately, and Francois Lebel, M.D., is stepping down from his position as Chief Medical Officer (CMO) and Executive Vice President of Research & Development, effective Oct. 26.


Ziopharm and Precigen Redefine Relationships, Announce New License Agreement
Posted on Tuesday October 09, 2018

Ziopharm to Host Conference Call at 8 a.m. Through the new agreement, Ziopharm will primarily focus its resources on developing its Controlled IL-12 and Sleeping Beauty (SB) T-cell receptor (TCR) platform technologies which have the capability to treat solid tumors, while Intrexon further establishes Precigen as a therapeutics company concentrating on immuno-oncology, autoimmune and infectious disease therapies. With this exclusive license, Ziopharm now has full developmental control and exclusivity utilizing SB for TCRs targeted towards neoantigens and public antigens.


Ziopharm Oncology to Present at the 2018 Cantor Fitzgerald Global Healthcare Conference
Posted on Tuesday September 25, 2018

Ziopharm Oncology, Inc. (ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer, will present at the Cantor Fitzgerald 2018 Global Healthcare Conference in New York on Tuesday, Oct. 2, at 2:15 p.m. ET. Ziopharm Oncology is a Boston-based biotechnology company focused on the development of next-generation immunotherapies utilizing gene- and cell-based therapies to treat patients with cancer. In partnership with Precigen Inc., a wholly-owned subsidiary of Intrexon Corporation (XON), Ziopharm is focused on the development of two platform technologies designed to deliver safe, effective and scalable cell- and viral-based therapies for the treatment of multiple cancer types: Controlled IL-12 and Sleeping Beauty for genetically modifying T cells.


Should You Have ZIOPHARM Oncology Inc’s (NASDAQ:ZIOP) In Your Portfolio?
Posted on Thursday September 20, 2018

If you own shares in ZIOPHARM Oncology Inc (NASDAQ:ZIOP) then it’s worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measureRead More...


Stock Market & Investing Books

Enter a stock symbol to view the stock details.